Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyUrapidil
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Urapidil
- Accession Number
- DB12661
- Type
- Small Molecule
- Groups
- Investigational
- Description
Urapidil has been investigated for the treatment of Hypertension During Pre-Eclampsia.
- Structure
Structure for DB12661 (Urapidil)
- Synonyms
- Not Available
- Categories
- Adrenergic Agents
- Adrenergic alpha-1 Receptor Antagonists
- Adrenergic alpha-Antagonists
- Adrenergic Antagonists
- Alpha-Adrenoreceptor Antagonists
- Antiadrenergic Agents, Peripherally Acting
- Antihypertensive Agents
- Cardiovascular Agents
- Cardiovascular System
- Neurotransmitter Agents
- Serotonin Agents
- Serotonin Receptor Agonists
- Vasodilator Agents
- UNII
- A78GF17HJS
- CAS number
- 34661-75-1
- Weight
- Average: 387.484
Monoisotopic: 387.227039814 - Chemical Formula
- C20H29N5O3
- InChI Key
- ICMGLRUYEQNHPF-UHFFFAOYSA-N
- InChI
- InChI=1S/C20H29N5O3/c1-22-18(15-19(26)23(2)20(22)27)21-9-6-10-24-11-13-25(14-12-24)16-7-4-5-8-17(16)28-3/h4-5,7-8,15,21H,6,9-14H2,1-3H3
- IUPAC Name
- 6-({3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl}amino)-1,3-dimethyl-1,2,3,4-tetrahydropyrimidine-2,4-dione
- SMILES
- COC1=CC=CC=C1N1CCN(CCCNC2=CC(=O)N(C)C(=O)N2C)CC1
Pharmacology
- Indication
- Not Available
- Structured Indications
- Not Available
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Urapidil. Experimental Acebutolol Acebutolol may increase the orthostatic hypotensive activities of Urapidil. Approved, Investigational Acemetacin The therapeutic efficacy of Urapidil can be decreased when used in combination with Acemetacin. Approved, Experimental, Investigational Adrafinil Urapidil may decrease the vasoconstricting activities of Adrafinil. Withdrawn Agmatine The risk or severity of hypotension can be increased when Urapidil is combined with Agmatine. Experimental, Investigational Alfuzosin Alfuzosin may increase the hypotensive activities of Urapidil. Approved, Investigational Aliskiren Urapidil may increase the hypotensive activities of Aliskiren. Approved, Investigational Alprenolol Alprenolol may increase the orthostatic hypotensive activities of Urapidil. Approved, Withdrawn Ambrisentan Urapidil may increase the hypotensive activities of Ambrisentan. Approved, Investigational Amibegron Urapidil may decrease the vasoconstricting activities of Amibegron. Investigational Amifostine Urapidil may increase the hypotensive activities of Amifostine. Approved, Investigational Amiodarone The risk or severity of hypotension can be increased when Urapidil is combined with Amiodarone. Approved, Investigational Amitraz Urapidil may decrease the vasoconstricting activities of Amitraz. Vet Approved Amlodipine Urapidil may increase the hypotensive activities of Amlodipine. Approved Amphetamine Amphetamine may increase the hypotensive activities of Urapidil. Approved, Illicit, Investigational Amrinone The risk or severity of hypotension can be increased when Urapidil is combined with Amrinone. Approved Anisodamine Urapidil may decrease the vasoconstricting activities of Anisodamine. Investigational Apraclonidine Urapidil may decrease the vasoconstricting activities of Apraclonidine. Approved Aranidipine The risk or severity of hypotension can be increased when Urapidil is combined with Aranidipine. Approved, Investigational Arbutamine Urapidil may decrease the vasoconstricting activities of Arbutamine. Approved Arformoterol Urapidil may decrease the vasoconstricting activities of Arformoterol. Approved, Investigational Arotinolol Arotinolol may increase the orthostatic hypotensive activities of Urapidil. Investigational Atenolol Atenolol may increase the orthostatic hypotensive activities of Urapidil. Approved Avanafil Avanafil may increase the hypotensive activities of Urapidil. Approved Azelnidipine The risk or severity of hypotension can be increased when Urapidil is combined with Azelnidipine. Approved, Investigational Azimilide The risk or severity of hypotension can be increased when Urapidil is combined with Azimilide. Investigational Barnidipine Urapidil may increase the antihypertensive activities of Barnidipine. Approved Befunolol Befunolol may increase the orthostatic hypotensive activities of Urapidil. Experimental Benazepril Urapidil may increase the hypotensive activities of Benazepril. Approved, Investigational Bencyclane The risk or severity of hypotension can be increased when Urapidil is combined with Bencyclane. Experimental Bendroflumethiazide Urapidil may increase the hypotensive activities of Bendroflumethiazide. Approved Benidipine The risk or severity of hypotension can be increased when Urapidil is combined with Benidipine. Approved, Investigational Benmoxin Benmoxin may increase the hypotensive activities of Urapidil. Withdrawn Bepridil Urapidil may increase the hypotensive activities of Bepridil. Approved, Withdrawn Betaxolol Betaxolol may increase the orthostatic hypotensive activities of Urapidil. Approved, Investigational Bethanidine Bethanidine may increase the hypotensive activities of Urapidil. Approved Bevantolol Bevantolol may increase the orthostatic hypotensive activities of Urapidil. Approved Bietaserpine Urapidil may increase the hypotensive activities of Bietaserpine. Experimental Bimatoprost Urapidil may increase the hypotensive activities of Bimatoprost. Approved, Investigational Bioallethrin The risk or severity of hypotension can be increased when Urapidil is combined with Bioallethrin. Approved, Experimental Bisoprolol Bisoprolol may increase the orthostatic hypotensive activities of Urapidil. Approved Bitolterol Urapidil may decrease the vasoconstricting activities of Bitolterol. Withdrawn Bopindolol Bopindolol may increase the orthostatic hypotensive activities of Urapidil. Approved Bosentan Bosentan may increase the hypotensive activities of Urapidil. Approved, Investigational BQ-123 Urapidil may increase the hypotensive activities of BQ-123. Investigational Bretylium Urapidil may increase the hypotensive activities of Bretylium. Approved Brimonidine Brimonidine may increase the antihypertensive activities of Urapidil. Approved Brofaromine Brofaromine may increase the hypotensive activities of Urapidil. Experimental Bucindolol Urapidil may increase the antihypertensive activities of Bucindolol. Investigational Bufuralol Bufuralol may increase the orthostatic hypotensive activities of Urapidil. Experimental, Investigational Bunazosin Bunazosin may increase the antihypertensive activities of Urapidil. Investigational Bupranolol Bupranolol may increase the orthostatic hypotensive activities of Urapidil. Approved Cadralazine Urapidil may increase the hypotensive activities of Cadralazine. Experimental Cafedrine Urapidil may increase the hypotensive activities of Cafedrine. Investigational Candesartan Urapidil may increase the hypotensive activities of Candesartan. Experimental Candesartan cilexetil Urapidil may increase the hypotensive activities of Candesartan cilexetil. Approved Candoxatril Urapidil may increase the hypotensive activities of Candoxatril. Experimental Captopril Urapidil may increase the hypotensive activities of Captopril. Approved Carboxyamidotriazole The risk or severity of hypotension can be increased when Urapidil is combined with Carboxyamidotriazole. Investigational Caroverine The risk or severity of hypotension can be increased when Urapidil is combined with Caroverine. Experimental Caroxazone Caroxazone may increase the hypotensive activities of Urapidil. Withdrawn Carteolol Carteolol may increase the orthostatic hypotensive activities of Urapidil. Approved Carvedilol Carvedilol may increase the antihypertensive activities of Urapidil. Approved, Investigational Celiprolol Celiprolol may increase the orthostatic hypotensive activities of Urapidil. Approved, Investigational Chlorothiazide Urapidil may increase the hypotensive activities of Chlorothiazide. Approved, Vet Approved Chlorthalidone Urapidil may increase the hypotensive activities of Chlorthalidone. Approved Cicletanine Urapidil may increase the hypotensive activities of Cicletanine. Investigational Cilazapril Urapidil may increase the hypotensive activities of Cilazapril. Approved Cilnidipine The risk or severity of hypotension can be increased when Urapidil is combined with Cilnidipine. Approved, Investigational Cinnarizine The risk or severity of hypotension can be increased when Urapidil is combined with Cinnarizine. Approved, Investigational Cirazoline Urapidil may decrease the vasoconstricting activities of Cirazoline. Experimental Clenbuterol Urapidil may decrease the vasoconstricting activities of Clenbuterol. Approved, Investigational, Vet Approved Clevidipine The risk or severity of hypotension can be increased when Urapidil is combined with Clevidipine. Approved, Investigational Clonidine Urapidil may decrease the vasoconstricting activities of Clonidine. Approved Cloranolol Cloranolol may increase the orthostatic hypotensive activities of Urapidil. Experimental Cryptenamine Urapidil may increase the hypotensive activities of Cryptenamine. Approved Cyclandelate The risk or severity of hypotension can be increased when Urapidil is combined with Cyclandelate. Approved Cyclopenthiazide Urapidil may increase the hypotensive activities of Cyclopenthiazide. Experimental Cyclothiazide Urapidil may increase the hypotensive activities of Cyclothiazide. Approved Dapoxetine Dapoxetine may increase the orthostatic hypotensive activities of Urapidil. Investigational Darodipine The risk or severity of hypotension can be increased when Urapidil is combined with Darodipine. Experimental Debrisoquin Debrisoquin may increase the hypotensive activities of Urapidil. Approved, Investigational Delapril Urapidil may increase the hypotensive activities of Delapril. Experimental Deserpidine Urapidil may increase the hypotensive activities of Deserpidine. Approved Detomidine Urapidil may decrease the vasoconstricting activities of Detomidine. Vet Approved Dexmedetomidine Urapidil may decrease the vasoconstricting activities of Dexmedetomidine. Approved, Vet Approved Diazoxide Diazoxide may increase the hypotensive activities of Urapidil. Approved Diethylnorspermine Urapidil may increase the hypotensive activities of Diethylnorspermine. Investigational Dihydralazine Dihydralazine may increase the hypotensive activities of Urapidil. Approved, Investigational Diltiazem Urapidil may increase the hypotensive activities of Diltiazem. Approved, Investigational Dipivefrin Urapidil may decrease the vasoconstricting activities of Dipivefrin. Approved Dobutamine Urapidil may decrease the vasoconstricting activities of Dobutamine. Approved Dopexamine Urapidil may decrease the vasoconstricting activities of Dopexamine. Approved, Investigational Dorzolamide Urapidil may increase the hypotensive activities of Dorzolamide. Approved Dotarizine The risk or severity of hypotension can be increased when Urapidil is combined with Dotarizine. Investigational Doxazosin Doxazosin may increase the antihypertensive activities of Urapidil. Approved Droxidopa Urapidil may decrease the vasoconstricting activities of Droxidopa. Approved, Investigational Efonidipine Urapidil may increase the hypotensive activities of Efonidipine. Approved, Investigational Enalapril Urapidil may increase the hypotensive activities of Enalapril. Approved, Vet Approved Enalaprilat Urapidil may increase the hypotensive activities of Enalaprilat. Approved Endralazine Urapidil may increase the hypotensive activities of Endralazine. Experimental Epanolol Epanolol may increase the orthostatic hypotensive activities of Urapidil. Experimental Eperisone The risk or severity of hypotension can be increased when Urapidil is combined with Eperisone. Approved, Investigational Ephedrine Urapidil may decrease the vasoconstricting activities of Ephedrine. Approved Epinastine Urapidil may decrease the vasoconstricting activities of Epinastine. Approved, Investigational Epinephrine Urapidil may decrease the vasoconstricting activities of Epinephrine. Approved, Vet Approved Epoprostenol Urapidil may increase the hypotensive activities of Epoprostenol. Approved Eprosartan Urapidil may increase the hypotensive activities of Eprosartan. Approved Ergotamine Urapidil may decrease the vasoconstricting activities of Ergotamine. Approved Esmolol Esmolol may increase the orthostatic hypotensive activities of Urapidil. Approved Ethosuximide The risk or severity of hypotension can be increased when Urapidil is combined with Ethosuximide. Approved Etilefrine Urapidil may decrease the vasoconstricting activities of Etilefrine. Withdrawn Felodipine Urapidil may increase the hypotensive activities of Felodipine. Approved, Investigational Fendiline The risk or severity of hypotension can be increased when Urapidil is combined with Fendiline. Withdrawn Fenoldopam Urapidil may increase the hypotensive activities of Fenoldopam. Approved Fenoterol Urapidil may decrease the vasoconstricting activities of Fenoterol. Approved, Investigational Ferulic acid Urapidil may increase the hypotensive activities of Ferulic acid. Experimental Fish oil The risk or severity of hypotension can be increased when Urapidil is combined with Fish oil. Approved, Nutraceutical Flunarizine The risk or severity of hypotension can be increased when Urapidil is combined with Flunarizine. Approved Fluspirilene The risk or severity of hypotension can be increased when Urapidil is combined with Fluspirilene. Approved, Investigational Formoterol Urapidil may decrease the vasoconstricting activities of Formoterol. Approved, Investigational Fosinopril Urapidil may increase the hypotensive activities of Fosinopril. Approved Furazolidone Furazolidone may increase the hypotensive activities of Urapidil. Approved, Investigational, Vet Approved Gabapentin The risk or severity of hypotension can be increased when Urapidil is combined with Gabapentin. Approved, Investigational Gallopamil The risk or severity of hypotension can be increased when Urapidil is combined with Gallopamil. Investigational Guanabenz Urapidil may decrease the vasoconstricting activities of Guanabenz. Approved, Investigational Guanadrel Urapidil may increase the hypotensive activities of Guanadrel. Approved Guanazodine Urapidil may increase the hypotensive activities of Guanazodine. Experimental Guanethidine Urapidil may increase the hypotensive activities of Guanethidine. Approved Guanfacine Urapidil may decrease the vasoconstricting activities of Guanfacine. Approved, Investigational Guanoclor Urapidil may increase the hypotensive activities of Guanoclor. Experimental Guanoxabenz Urapidil may increase the hypotensive activities of Guanoxabenz. Experimental Guanoxan Urapidil may increase the hypotensive activities of Guanoxan. Experimental Harmaline Harmaline may increase the hypotensive activities of Urapidil. Experimental Hexamethonium Urapidil may increase the hypotensive activities of Hexamethonium. Experimental Hexoprenaline Urapidil may decrease the vasoconstricting activities of Hexoprenaline. Approved, Withdrawn Higenamine Urapidil may decrease the vasoconstricting activities of Higenamine. Investigational Hydracarbazine Hydracarbazine may increase the hypotensive activities of Urapidil. Experimental Hydralazine Hydralazine may increase the hypotensive activities of Urapidil. Approved Hydrochlorothiazide Urapidil may increase the hypotensive activities of Hydrochlorothiazide. Approved, Vet Approved Hydroflumethiazide Urapidil may increase the hypotensive activities of Hydroflumethiazide. Approved, Investigational Iloprost Iloprost may increase the hypotensive activities of Urapidil. Approved, Investigational Imidapril Urapidil may increase the hypotensive activities of Imidapril. Investigational Indapamide Urapidil may increase the hypotensive activities of Indapamide. Approved Indenolol Indenolol may increase the orthostatic hypotensive activities of Urapidil. Withdrawn Indoramin Indoramin may increase the antihypertensive activities of Urapidil. Withdrawn Iproclozide Iproclozide may increase the hypotensive activities of Urapidil. Withdrawn Iproniazid Iproniazid may increase the hypotensive activities of Urapidil. Withdrawn Irbesartan Urapidil may increase the hypotensive activities of Irbesartan. Approved, Investigational Isocarboxazid Isocarboxazid may increase the hypotensive activities of Urapidil. Approved Isoetarine Urapidil may decrease the vasoconstricting activities of Isoetarine. Approved Isoprenaline Urapidil may decrease the vasoconstricting activities of Isoprenaline. Approved, Investigational Isoxsuprine Urapidil may decrease the vasoconstricting activities of Isoxsuprine. Approved, Withdrawn Isradipine Urapidil may increase the hypotensive activities of Isradipine. Approved, Investigational Ketanserin Ketanserin may increase the hypotensive activities of Urapidil. Investigational Labetalol Labetalol may increase the antihypertensive activities of Urapidil. Approved Lacidipine Urapidil may increase the hypotensive activities of Lacidipine. Approved, Investigational Lamotrigine The risk or severity of hypotension can be increased when Urapidil is combined with Lamotrigine. Approved, Investigational Landiolol Landiolol may increase the orthostatic hypotensive activities of Urapidil. Investigational Latanoprost Urapidil may increase the hypotensive activities of Latanoprost. Approved, Investigational Lercanidipine Urapidil may increase the hypotensive activities of Lercanidipine. Approved, Investigational Levetiracetam The risk or severity of hypotension can be increased when Urapidil is combined with Levetiracetam. Approved, Investigational Lidoflazine The risk or severity of hypotension can be increased when Urapidil is combined with Lidoflazine. Experimental Linsidomine Urapidil may increase the hypotensive activities of Linsidomine. Experimental Lisinopril Urapidil may increase the hypotensive activities of Lisinopril. Approved, Investigational Lofexidine Urapidil may decrease the vasoconstricting activities of Lofexidine. Approved, Investigational Loperamide The risk or severity of hypotension can be increased when Urapidil is combined with Loperamide. Approved Losartan Urapidil may increase the hypotensive activities of Losartan. Approved Macitentan Urapidil may increase the hypotensive activities of Macitentan. Approved Magnesium sulfate The risk or severity of hypotension can be increased when Urapidil is combined with Magnesium sulfate. Approved, Investigational, Vet Approved Manidipine Urapidil may increase the hypotensive activities of Manidipine. Approved, Investigational Mebanazine Mebanazine may increase the hypotensive activities of Urapidil. Withdrawn Mecamylamine Mecamylamine may increase the hypotensive activities of Urapidil. Approved, Investigational Medetomidine Urapidil may decrease the vasoconstricting activities of Medetomidine. Vet Approved Mephentermine Urapidil may decrease the vasoconstricting activities of Mephentermine. Approved Mepindolol Mepindolol may increase the orthostatic hypotensive activities of Urapidil. Experimental Metaraminol Urapidil may decrease the vasoconstricting activities of Metaraminol. Approved, Investigational Methoserpidine Urapidil may increase the hypotensive activities of Methoserpidine. Experimental Methoxamine Urapidil may decrease the vasoconstricting activities of Methoxamine. Approved, Investigational Methoxyphenamine Urapidil may decrease the vasoconstricting activities of Methoxyphenamine. Experimental Methsuximide The risk or severity of hypotension can be increased when Urapidil is combined with Methsuximide. Approved Methyldopa Urapidil may decrease the vasoconstricting activities of Methyldopa. Approved Methylene blue Methylene blue may increase the hypotensive activities of Urapidil. Approved, Investigational Methylphenidate Methylphenidate may decrease the antihypertensive activities of Urapidil. Approved, Investigational Metipranolol Urapidil may increase the hypotensive activities of Metipranolol. Approved Metolazone Urapidil may increase the hypotensive activities of Metolazone. Approved Metoprolol Metoprolol may increase the orthostatic hypotensive activities of Urapidil. Approved, Investigational Metyrosine Urapidil may increase the hypotensive activities of Metyrosine. Approved Mibefradil Urapidil may increase the hypotensive activities of Mibefradil. Investigational, Withdrawn Midodrine Urapidil may decrease the vasoconstricting activities of Midodrine. Approved Minaprine Minaprine may increase the hypotensive activities of Urapidil. Approved Minoxidil Minoxidil may increase the hypotensive activities of Urapidil. Approved, Investigational Mirabegron Urapidil may decrease the vasoconstricting activities of Mirabegron. Approved Mirodenafil Mirodenafil may increase the hypotensive activities of Urapidil. Investigational Moclobemide Moclobemide may increase the hypotensive activities of Urapidil. Approved, Investigational Moexipril Urapidil may increase the hypotensive activities of Moexipril. Approved Molsidomine Molsidomine may increase the hypotensive activities of Urapidil. Approved, Investigational Moxonidine Moxonidine may increase the hypotensive activities of Urapidil. Approved, Investigational Muzolimine Urapidil may increase the hypotensive activities of Muzolimine. Experimental Nadolol Nadolol may increase the orthostatic hypotensive activities of Urapidil. Approved Naftopidil Urapidil may increase the hypotensive activities of Naftopidil. Investigational Naphazoline Urapidil may decrease the vasoconstricting activities of Naphazoline. Approved Nebivolol Nebivolol may increase the orthostatic hypotensive activities of Urapidil. Approved, Investigational Nialamide Nialamide may increase the hypotensive activities of Urapidil. Withdrawn Nicardipine Urapidil may increase the hypotensive activities of Nicardipine. Approved, Investigational Nicorandil Urapidil may increase the hypotensive activities of Nicorandil. Approved, Investigational Nifedipine The risk or severity of hypotension can be increased when Urapidil is combined with Nifedipine. Approved Niguldipine Urapidil may increase the hypotensive activities of Niguldipine. Experimental Niludipine The risk or severity of hypotension can be increased when Urapidil is combined with Niludipine. Experimental Nilvadipine Urapidil may increase the hypotensive activities of Nilvadipine. Approved, Investigational Nimesulide The risk or severity of hypotension can be increased when Urapidil is combined with Nimesulide. Approved, Investigational, Withdrawn Nimodipine Urapidil may increase the hypotensive activities of Nimodipine. Approved, Investigational Nisoldipine Urapidil may increase the hypotensive activities of Nisoldipine. Approved Nitrendipine Urapidil may increase the hypotensive activities of Nitrendipine. Approved, Investigational Nitroprusside Nitroprusside may increase the hypotensive activities of Urapidil. Approved, Investigational Norepinephrine Urapidil may decrease the vasoconstricting activities of Norepinephrine. Approved Norfenefrine Urapidil may decrease the vasoconstricting activities of Norfenefrine. Experimental Nylidrin Urapidil may decrease the vasoconstricting activities of Nylidrin. Approved Obinutuzumab Urapidil may increase the hypotensive activities of Obinutuzumab. Approved, Investigational Octamoxin Octamoxin may increase the hypotensive activities of Urapidil. Withdrawn Octopamine Urapidil may decrease the vasoconstricting activities of Octopamine. Experimental Olmesartan Urapidil may increase the hypotensive activities of Olmesartan. Approved, Investigational Olodaterol Urapidil may decrease the vasoconstricting activities of Olodaterol. Approved Omapatrilat Urapidil may increase the hypotensive activities of Omapatrilat. Investigational Orciprenaline Urapidil may decrease the vasoconstricting activities of Orciprenaline. Approved Otilonium The risk or severity of hypotension can be increased when Urapidil is combined with Otilonium. Experimental, Investigational Oxprenolol Oxprenolol may increase the orthostatic hypotensive activities of Urapidil. Approved Oxyfedrine Urapidil may decrease the vasoconstricting activities of Oxyfedrine. Experimental Oxymetazoline Urapidil may decrease the vasoconstricting activities of Oxymetazoline. Approved, Investigational Pargyline Pargyline may increase the hypotensive activities of Urapidil. Approved Penbutolol Penbutolol may increase the orthostatic hypotensive activities of Urapidil. Approved, Investigational Pentolinium Urapidil may increase the hypotensive activities of Pentolinium. Approved Pentoxifylline Pentoxifylline may increase the hypotensive activities of Urapidil. Approved, Investigational Perindopril Urapidil may increase the hypotensive activities of Perindopril. Approved Phenelzine Phenelzine may increase the hypotensive activities of Urapidil. Approved Pheniprazine Pheniprazine may increase the hypotensive activities of Urapidil. Withdrawn Phenoxybenzamine Urapidil may increase the hypotensive activities of Phenoxybenzamine. Approved Phenoxypropazine Phenoxypropazine may increase the hypotensive activities of Urapidil. Withdrawn Phentolamine Urapidil may increase the hypotensive activities of Phentolamine. Approved Phenylephrine Urapidil may decrease the vasoconstricting activities of Phenylephrine. Approved Phenylpropanolamine Urapidil may decrease the vasoconstricting activities of Phenylpropanolamine. Approved, Vet Approved, Withdrawn Pinacidil Pinacidil may increase the hypotensive activities of Urapidil. Approved Pinaverium The risk or severity of hypotension can be increased when Urapidil is combined with Pinaverium. Approved Pindolol Pindolol may increase the orthostatic hypotensive activities of Urapidil. Approved, Investigational Pirbuterol Urapidil may decrease the vasoconstricting activities of Pirbuterol. Approved Pirlindole Pirlindole may increase the hypotensive activities of Urapidil. Approved Pivhydrazine Pivhydrazine may increase the hypotensive activities of Urapidil. Withdrawn Platelet Activating Factor Platelet Activating Factor may increase the orthostatic hypotensive activities of Urapidil. Experimental Polythiazide Urapidil may increase the hypotensive activities of Polythiazide. Approved Practolol Practolol may increase the orthostatic hypotensive activities of Urapidil. Approved Prazosin Prazosin may increase the antihypertensive activities of Urapidil. Approved Prenalterol Urapidil may decrease the vasoconstricting activities of Prenalterol. Experimental Prenylamine The risk or severity of hypotension can be increased when Urapidil is combined with Prenylamine. Withdrawn Procarbazine Procarbazine may increase the hypotensive activities of Urapidil. Approved, Investigational Procaterol Urapidil may decrease the vasoconstricting activities of Procaterol. Approved, Investigational Propranolol Propranolol may increase the orthostatic hypotensive activities of Urapidil. Approved, Investigational Pseudoephedrine Urapidil may decrease the vasoconstricting activities of Pseudoephedrine. Approved Quinapril Urapidil may increase the hypotensive activities of Quinapril. Approved, Investigational Quinine Quinine may increase the hypotensive activities of Urapidil. Approved Racepinephrine Urapidil may decrease the vasoconstricting activities of Racepinephrine. Approved Ractopamine Urapidil may decrease the vasoconstricting activities of Ractopamine. Vet Approved Ramipril Urapidil may increase the hypotensive activities of Ramipril. Approved Rasagiline Rasagiline may increase the hypotensive activities of Urapidil. Approved Remikiren Urapidil may increase the hypotensive activities of Remikiren. Approved Reproterol Urapidil may decrease the vasoconstricting activities of Reproterol. Investigational Rescinnamine Urapidil may increase the hypotensive activities of Rescinnamine. Approved Reserpine Reserpine may increase the hypotensive activities of Urapidil. Approved, Investigational Rilmenidine Urapidil may decrease the vasoconstricting activities of Rilmenidine. Approved, Investigational Rimiterol Urapidil may decrease the vasoconstricting activities of Rimiterol. Experimental Riociguat Urapidil may increase the hypotensive activities of Riociguat. Approved Ritobegron Urapidil may decrease the vasoconstricting activities of Ritobegron. Investigational Ritodrine Urapidil may decrease the vasoconstricting activities of Ritodrine. Approved, Investigational Rituximab Urapidil may increase the hypotensive activities of Rituximab. Approved Romifidine Urapidil may decrease the vasoconstricting activities of Romifidine. Vet Approved Safrazine Safrazine may increase the hypotensive activities of Urapidil. Withdrawn Salbutamol Urapidil may decrease the vasoconstricting activities of Salbutamol. Approved, Vet Approved Salmeterol Urapidil may decrease the vasoconstricting activities of Salmeterol. Approved Saprisartan Urapidil may increase the hypotensive activities of Saprisartan. Experimental Selegiline Selegiline may increase the hypotensive activities of Urapidil. Approved, Investigational, Vet Approved Seletracetam The risk or severity of hypotension can be increased when Urapidil is combined with Seletracetam. Investigational Selexipag Urapidil may increase the hypotensive activities of Selexipag. Approved Sildenafil Sildenafil may increase the hypotensive activities of Urapidil. Approved, Investigational Silodosin Silodosin may increase the antihypertensive activities of Urapidil. Approved Sitaxentan Urapidil may increase the hypotensive activities of Sitaxentan. Approved, Investigational, Withdrawn Solabegron Urapidil may decrease the vasoconstricting activities of Solabegron. Investigational Sotalol Sotalol may increase the orthostatic hypotensive activities of Urapidil. Approved Spirapril Urapidil may increase the hypotensive activities of Spirapril. Approved Synephrine Urapidil may decrease the vasoconstricting activities of Synephrine. Experimental Tadalafil Tadalafil may increase the hypotensive activities of Urapidil. Approved, Investigational Talinolol Talinolol may increase the orthostatic hypotensive activities of Urapidil. Investigational Tamsulosin Tamsulosin may increase the antihypertensive activities of Urapidil. Approved, Investigational Telmisartan Urapidil may increase the hypotensive activities of Telmisartan. Approved, Investigational Temocapril Urapidil may increase the hypotensive activities of Temocapril. Experimental, Investigational Terazosin Terazosin may increase the antihypertensive activities of Urapidil. Approved Terbutaline Urapidil may decrease the vasoconstricting activities of Terbutaline. Approved Terlipressin Urapidil may increase the hypotensive activities of Terlipressin. Approved, Investigational Terodiline The risk or severity of hypotension can be increased when Urapidil is combined with Terodiline. Experimental Tertatolol Tertatolol may increase the orthostatic hypotensive activities of Urapidil. Experimental Tetrahydropalmatine Urapidil may increase the hypotensive activities of Tetrahydropalmatine. Investigational Theodrenaline Urapidil may increase the hypotensive activities of Theodrenaline. Investigational Tibolone Urapidil may increase the hypotensive activities of Tibolone. Approved, Investigational Ticrynafen Urapidil may increase the hypotensive activities of Ticrynafen. Withdrawn Timolol Timolol may increase the orthostatic hypotensive activities of Urapidil. Approved Tizanidine Urapidil may decrease the vasoconstricting activities of Tizanidine. Approved, Investigational Tolazoline Urapidil may increase the hypotensive activities of Tolazoline. Approved, Vet Approved Tolfenamic Acid The risk or severity of hypotension can be increased when Urapidil is combined with Tolfenamic Acid. Approved, Investigational Tolonidine Urapidil may increase the hypotensive activities of Tolonidine. Experimental Toloxatone Toloxatone may increase the hypotensive activities of Urapidil. Approved Torasemide Urapidil may increase the hypotensive activities of Torasemide. Approved Trandolapril Urapidil may increase the hypotensive activities of Trandolapril. Approved Tranilast The risk or severity of hypotension can be increased when Urapidil is combined with Tranilast. Approved, Investigational Tranylcypromine Tranylcypromine may increase the hypotensive activities of Urapidil. Approved, Investigational Travoprost Urapidil may increase the hypotensive activities of Travoprost. Approved Treprostinil Urapidil may increase the hypotensive activities of Treprostinil. Approved, Investigational Tretoquinol Urapidil may decrease the vasoconstricting activities of Tretoquinol. Experimental Trichlormethiazide Urapidil may increase the hypotensive activities of Trichlormethiazide. Approved, Vet Approved Trimazosin Trimazosin may increase the antihypertensive activities of Urapidil. Experimental Trimebutine The risk or severity of hypotension can be increased when Urapidil is combined with Trimebutine. Approved Trimethadione The risk or severity of hypotension can be increased when Urapidil is combined with Trimethadione. Approved Trimethaphan Trimethaphan may increase the hypotensive activities of Urapidil. Approved, Investigational Tulobuterol Urapidil may decrease the vasoconstricting activities of Tulobuterol. Investigational Udenafil Udenafil may increase the hypotensive activities of Urapidil. Approved, Investigational Unoprostone Urapidil may increase the hypotensive activities of Unoprostone. Approved, Investigational Valsartan Urapidil may increase the hypotensive activities of Valsartan. Approved, Investigational Vardenafil Vardenafil may increase the hypotensive activities of Urapidil. Approved Verapamil The risk or severity of hypotension can be increased when Urapidil is combined with Verapamil. Approved Vincamine Urapidil may increase the hypotensive activities of Vincamine. Experimental Vinpocetine Urapidil may increase the hypotensive activities of Vinpocetine. Investigational WIN 55212-2 The risk or severity of hypotension can be increased when Urapidil is combined with WIN 55212-2. Experimental Xamoterol Urapidil may decrease the vasoconstricting activities of Xamoterol. Experimental Xipamide Urapidil may increase the hypotensive activities of Xipamide. Experimental Xylazine Urapidil may decrease the vasoconstricting activities of Xylazine. Vet Approved Xylometazoline Urapidil may increase the hypotensive activities of Xylometazoline. Approved, Investigational Yohimbine Yohimbine may decrease the antihypertensive activities of Urapidil. Approved, Investigational, Vet Approved Ziconotide The risk or severity of hypotension can be increased when Urapidil is combined with Ziconotide. Approved Zofenopril Urapidil may increase the hypotensive activities of Zofenopril. Experimental Zonisamide The risk or severity of hypotension can be increased when Urapidil is combined with Zonisamide. Approved, Investigational - Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
- ATC Codes
- C02CA06 — Urapidil
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Recruiting Treatment Aortic Dissection Type B / High Blood Pressure (Hypertension) 1 3 Recruiting Treatment High Blood Pressure (Hypertension) / Preeclampsia 1 3 Unknown Status Treatment Hypertension During Pre-Eclampsia 1 4 Recruiting Treatment Nontraumatic Intracerebral Hemorrhage, Multiple Localized 1 Not Available Completed Treatment CVA (Cerebrovascular Accident) / Intracerebral Hemorrhage / Intracranial Hemorrhages 1 Not Available Recruiting Diagnostic General Surgery 1 Not Available Recruiting Treatment Aging / Anaesthesia therapy / Blood Loss,Surgical / Blood Pressures / General Surgery / Postoperative Delirium 1 Not Available Recruiting Treatment Scheduled Laparoscopic Surgery 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.541 mg/mL ALOGPS logP 1.69 ALOGPS logP 1.18 ChemAxon logS -2.9 ALOGPS pKa (Strongest Basic) 8.11 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 6 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 68.36 Å2 ChemAxon Rotatable Bond Count 7 ChemAxon Refractivity 119.37 m3·mol-1 ChemAxon Polarizability 43.07 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-qTof , Positive LC-MS/MS Not Available MS/MS Spectrum - , positive LC-MS/MS splash10-000i-0439000000-1f066af9035f53bb2d89 MS/MS Spectrum - , positive LC-MS/MS splash10-0006-0900000000-2ccc838e7c2c252cb8ad
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Diazinanes
- Sub Class
- Piperazines
- Direct Parent
- Phenylpiperazines
- Alternative Parents
- N-arylpiperazines / Aminophenyl ethers / Methoxyanilines / Anisoles / Dialkylarylamines / Methoxybenzenes / Phenoxy compounds / N-alkylpiperazines / Aminopyrimidines and derivatives / Alkyl aryl ethers show 12 more
- Substituents
- Phenylpiperazine / N-arylpiperazine / Aminophenyl ether / Methoxyaniline / Tertiary aliphatic/aromatic amine / Phenoxy compound / Anisole / Dialkylarylamine / Aniline or substituted anilines / Phenol ether show 28 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
Drug created on October 20, 2016 17:31 / Updated on May 02, 2018 00:23